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Ischemia produced as a result of myocardial infarction might cause moderate or severe tissue death. Studies under development
propose grafting stem cells into the affected area and we hypothesize that this mechanism could be enhanced by the application
of a “bioactive implant.” The implant herein proposed consists of a thin porous elastomeric membrane, filled with self-assembling
nanofibers and human subcutaneous adipose tissue derived progenitor cells. We describe the development and characterization of
two elastomericmembranes: poly(ethyl acrylate) (PEA) and poly(caprolactone 2-(methacryloyloxy)ethyl ester) (PCLMA). Both are
a goodmaterial support to deliver cells within a soft self-assembling peptide and are elastic enough to withstand the stresses arising
from the heartbeat. Both developed composites (PEA and PCLMA, combined with self-assembling peptide) equally facilitate the
propagation of electrical pulses andmaintain their genetic profile of the seeded cells. Preliminary studies with small animal models
suggest that, at short times, the bioimplant shows good adhesion with the myocardium. After three days cells loaded in the patch
remain alive at the implanted site. We propose that the bioactive patch (elastomeric membranes with self-assembling peptide and
cells) could increase the efficacy of future cardiac cell therapy by improving cell immobilization and survival at the affected site.
1. Introduction
Heart failure (HF) is the end stage of most cardiovascular
diseases such as myocardial infarction (MI), which remains
the leading cause of premature death in the world. MI
is caused by a coronary artery occlusion that provokes a
reduction of blood supply to a portion of the myocardium,
developing a necrotic tissue with subsequent cell death [1].
Current therapies to reestablish blood supply to the affected
tissue include percutaneous coronary intervention (PCI),
stent placement, coronary artery bypass surgery, and drugs
administration. These treatments are capable of increasing
patients’ life expectancy but do not address the malfunction
due to muscular tissue death. In parallel, growing evidences
indicate that heart muscle is capable of regenerating through
the activation of cardiac stem cells or recruitment of stem cells
from other tissues [2], but it is not enough to compensate
the large-scale tissue loss after MI. The implantation of cells
with the hope that they will contribute to the generation
of new cardiac tissue appears as a good approach [3–5].
Several cell types are being tested as a potential source for
cell therapy including cardiac myocytes, skeletal myoblasts,
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embryonic stem cells (ESCs), and adult stem cells (ASCs)
[2, 6–12]. ASCs are present in various organs and tissues
including bone marrow [13, 14], adipose tissue [14–19], and
umbilical cord [20, 21]. Their principal advantages are based
on the fact that they can be isolated from the own patient
(autologous) and present a low risk of generating an immune
response and tumour development. The benefits reported
for cardiomyoplasty lead cells-based therapies to turn into
new hope in regenerative medicine and are undergoing
experimental and clinical trials. Unfortunately, until now,
cell transplantation has not achieved clear hemodynamic
benefits for myocardial diseases [22, 23]. The main obstacle
is that MI is an ischemic event followed by inflammatory
reaction, cytokines, and growth factors secretion. Therefore,
the transplantation of unprotected cells into this environment
results in significant cell death and low cell bioretention
and engraftment [24]. In this context, it seems suitable to
provide a safe environment (niche) for cell proliferation and
differentiation [23]. On the other hand, extracellular matrix
that gives structural strength to the LV is pathologically
modified (collagen type I decreased from 80% to 40%) and a
fibrous scar is formed [22]. Therefore, cardiomyocytes death
and scar formation modulate cardiac remodeling, which
refers to the changes in size, shape, structure, and physiology
of the heart. The regional structural changes lead to global
LV geometric change (dilated cardiomyopathy), altering fiber
direction and diminishing function. This contributes to an
increase in LV wall stress and mitral valve regurgitation [23].
Nowadays, a definitive statement about TE and bioma-
terials fields cannot be done, but there are some reliable
remarks referred to as materials-based platforms: they pro-
vide mechanical support to the damaged tissue while it
regenerates, can be modified to supply the bioactive agents
necessary for regeneration, and are able to restrict the cells to
the defect site guiding cell growth through surface chemistry
and topography [25]. RECATABI consortium proposes an
approach to address both the death of cardiomyocytes and the
remodelling of the heart muscle, with the aim to avoid heart
failure.The strategy consists in the development of a bioengi-
neering platform that contains three main components: (1)
elastomeric microporous membrane, which provides biome-
chanical support, (2) self-assembling peptide nanofiber gel,
which assures an adequatemicroenvironment, and (3) subcu-
taneous adipose tissue derived progenitor cells (subATDPCs)
[26]. Each of the components used to develop the patch is not
novelty by themselves but the right combination of them is.
Since the activity of heart muscle involves both con-
traction and dilation, the use of elastomeric membranes
may provide restoration forces. In addition, it is conceivable
that the transmitted stresses to the engrafted cells allow
deep structural and functional biointegration. With the hope
to introduce a new insight, materials used for the first
time in this field were examined. Complete biodegradation
of grafted scaffolds may compromise long-term limitation
of postischemic ventricular remodeling. For this reason,
nondegradable poly(ethyl acrylate) (PEA) with cylindrical
orthogonal pores and semidegradable poly(caprolactone 2-
(methacryloyloxy) ethyl ester) (PCLMA) with intercon-
nected spherical pores)membranes were tested [23]. PEA has
mechanical properties in the range of those of soft biological
tissues and it has shown excellent biological performance
in vitro with different cell types [27–33]. On the other
hand, PCLMA, also elastomeric at body temperature, has
a biologically stable skeleton with a biodegradable lateral
chain of caprolactone. It has been chosen to carry out these
preliminary in vivo experiments for its outstanding biological
behaviour, tested with several architectures and cell types,
both in vivo and in vitro [34–36]. The elasticity of these
polymers at physiological temperature is expected to permit
their adaptation to the curved ventricle over their entire
surface and follow its mechanical deformation. This elastic
property is crucial to not disturb the synchronous beating,
and at the same time, to avoid further dilatation. It is also
expected to allow the transfer of cells from the patch to the
myocardium due to its good tissue-material biointegration.
The RAD16-I self-assembling peptide nanofibers (proved
to be nontoxic in vivo [37]) were chosen to provide a suitable
environment to the implanted cells. It has been proved to
be a good candidate to culture different cell types in a 3D
environment [38–43], but its soft nature is a drawback for
its direct implantation as a cell vehicle. Nonetheless, it has
also been described to improve cell attachment in polymeric
scaffolds with respect to bare ones [44–46]. Here we propose
that the combination of RAD16-I and elastomeric scaffolds
should overcome the shortcomings of the gel combining the
advantages of both materials.
In the present work, we study the mechanical and bio-
logical properties of the developed bioactive patch as well
as a preliminary assessment of their early response, 3 days
after implantation, in small animal model (mice) of acute
MI. As stated, the elastomeric scaffolds employed possess
different architectures and compositions and thus slightly
different mechanical properties, degradability, and biological
performance. It is not intended to compare both structures
and chemistries, nor to study their effects in terms of cardiac
tissue regeneration, but to develop “proof of concept” and
demonstrate their suitability for the proposed application in
terms of manipulability and applicability onto the infarcted
area in the affected ventricle.
2. Materials and Methods
2.1. Preparation of the Elastomeric Membranes (Macroporous
Scaffolds). Poly(ethyl acrylate) (PEA) scaffolds with inter-
connected cylindrical orthogonal pores were obtained by
the template leaching method described before [47–49]. On
the other hand, poly(caprolactone 2-(methacryloyloxy)ethyl
ester) (PCLMA) scaffolds with spherical interconnected
pores were obtained by a procedure analogous to that fol-
lowed by Escobar Ivirico et al. [34]. For detailed methods,
please refer to the Supplementary Materials and Methods
section in the Supplementary Material available online at
http://dx.doi.org/10.1155/2015/804017. Finally, both materials
were washed with water and dried. PEA and PCLMA scaf-
folds were cut into samples having 5mm in diameter and
1mm thickness. Bulk films of both materials obtained by
polymerization in flat glass moulds were prepared to be
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used as controls. Materials to be used for cell culture were
previously sterilized with gamma radiation.
2.2. Preparation of the Elastomeric Membrane Prefilled with
RAD16-I Self-Assembling Peptide Nanofiber Scaffolds (Com-
posite). The self-assembling peptide RAD16-I (PuraMatrix
1% (w/v), BD Biosciences) was used to fill the PEA and
PCLMA scaffolds’ pores. Prior to its use, RAD16-I was placed
in a bath sonicator (Bandelin) for 30min at 25∘C applying
30W to decrease its viscosity and diluted to 0.15% (w/v).
Each elastomeric membrane was submerged in a RAD16-
I nanofiber peptide 0.15% solution, and with the help of
vacuum it was forced to penetrate in the hydrophobic
scaffolds. For the induction of the self-assembly of RAD16-I,
it is imperative to increase the ionic strength of themilieu. For
experiments without cells the self-assembling was induced
with phosphate buffer saline (PBS), but for the preparation
of bioimplant containing RAD16-I and cells the gelation
of RAD16-I was performed simultaneously to the seeding
process [45]. The process is explained in Section 2.4. The
efficient filling of membranes and gelling of RAD16-I were
assessed macroscopically by 𝛽-sheet structure staining with
Congo Red 0.1% (w/v) aqueous solution (Sigma Aldrich) for
20min followed by 30min of rinsing with PBS. Scaffolds with
only PBS in their pores were stained to be used as controls.
Next, cryoSEM images of the composites were obtained by
cryoSEM in a JSM5410 (JEOL Ltd., Tokyo, Japan) device
equipped with a cryounit (Oxford CT 1500) to confirm
the uniform filling of the scaffolds with the peptide gel.
Cross sections were previously obtained by immersion of
the samples in liquid nitrogen. Water within the peptide gel
was sublimated at −70∘C in the cryogenic unit for 15min in
vacuum. Samples were gold-sputtered and observed at 15 kV
and 15mm of working distance.
2.3. Structural, Mechanical, and Electrical Characterization of
the Elastomeric Membranes and Its Composites
2.3.1. Morphology. Bare PEA and PCLMA scaffolds were
fixed in 5% glutaraldehyde (Sigma Aldrich), dehydrated in
successive ethanol washes, dried using a CO
2
critical point,
and subsequently coated with gold. Samples were observed
in a JSM 6300 (JEOL Ltd., Tokyo, Japan) scanning electron
microscope (SEM) at 15 kV of acceleration voltage and 15mm
of working distance. The porosity of the bare scaffolds, 𝜋
(pore volume fraction), was obtained through the specific
volume of PEA (reciprocal of 1.13 g⋅cm−3) [50] or PCLMA,
respectively, V, the weight, 𝑚, and apparent (geometric)
volume, 𝑉, of the scaffolds as 𝜋 = 𝑉pores/𝑉 = 1 − 𝑚V/𝑉.
The specific volume of PCLMA was previously obtained
as follows: dry pieces of PCLMA films were weighed in
air, 𝑚, and immersed in n-octane (95%, Fluka, 𝜌n-octane =
0.703 g cm−3),𝑚󸀠, at room temperature. Specific volume was
calculated as the volume of n-octane displaced, obtained as
𝑉displ = (𝑚 −𝑚
󸀠)/𝜌n-octane, divided by the mass of the sample:
V = 𝑉displ/𝑚. Mettler AX 205 balance (Mettler-Toledo Inc.,
Columbus, OH, USA) with a sensitivity of 0.01mg, equipped
with a Mettler ME 33360 density accessory kit, was used.
2.3.2. Surface Wettability. The wettability of the elastomeric
membranes was assessed using aDrop ShapeAnalysis System
DSA100 (KRU¨SS, Deutschland). Briefly, water drops were
deposited on the membranes and the contact angle between
each drop and the surface of the membrane was measured.
2.3.3. Swelling andTensile Properties. Toquantify the swelling
of the scaffolds, 5mm diameter pieces of PEA and PCLMA
filmswere dryweighed and after different times of immersion
in phosphate-buffered saline (PBS) at 37∘C until no further
weight change was confirmed.The equilibriumwater content
(EWC) was obtained as the ratio of the mass of water
absorbed at equilibrium to the mass of dry polymer: EWC =
(𝑚wet − 𝑚)/𝑚. Pieces of PEA and PCLMA scaffolds and
their films were cut into 0.5 × 3 cm2 pieces, and tensile tests
were performed in a Microtest SCM3000 95 (Microtest SA,
Madrid, Spain) device at a deformation rate of 0.2mm/min
until fracture. The tensile modulus was obtained in each case
as the average of the slope in the strain-stress plots.
2.3.4. Study of the Impedance. Theelectrical impedance of the
membranes filled with hydrogel and submerged in 𝛼-MEM
medium (Sigma Aldrich) was measured at 10 kHz using
an impedance meter (Autolab, PGSTAT128N). Membranes
filled with physiologic serum (𝜌 = 0.625Ω⋅m) were also
measured to normalize impedance values (Ω) to resistivity
units (Ω⋅m). Platinum electrodes (0.5mm diameter) were
used for measurements performed at room temperature
(25∘C). The electrodes were introduced in parallel within the
plane membrane and separated by a distance of 5mm.
2.4. Cell Culture
2.4.1. Subcutaneous Adipose Tissue-Derived Progenitor Cells
(SubATDPCs) Isolation and Culture. SubATDPCs were iso-
lated from fat pads between skin and sternum from patients
undergoing cardiac surgery. Informed consent was obtained
from all subjects, and the study protocol conformed to the
principles outlined in the Declaration of Helsinki. Adipose
tissue biopsy samples were processed as previously described
[53, 54]. Refer to Supplementary Materials and Methods
section for detailed information. Adhered cells were grown
under standard conditions (37∘C and 5% CO
2
) in 𝛼-MEM
(Sigma Aldrich) supplemented with 10% foetal bovine serum
(Lonza), 1% penicillin-streptomycin (Labclinics), 1% L-
glutamine (Labclinics), and 5 𝜇g/mL Plasmocin (InvivoGen).
2.4.2. In Vitro Characterization of SubATDPCs Cultured in
Monolayer. SubATDPCs were characterized using clono-
genic and immunosuppression assays and immunopheno-
typical analysis. Additionally, assays for adipogenic and
osteogenic differentiation evaluation were performed. Please
refer to the online Supplementary Materials and Methods
section for details of the methods.
2.4.3. Cell Seeding in Elastomeric Membrane/Self-Assembling
Peptide Composites. SubATDPCs were seeded inside the
composites at passage 8. With this aim, the elastomeric
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membranes were filled with the peptide solution as explained
and placed in a 96-well plate. Then subATDPCs were
trypsinized and resuspended in a final concentration of
6.25⋅106 cells/mL in culture media. 40𝜇L of this suspension
was loaded on the top of each composite and incubated with
soft shake during 30min. This time allows the cells to diffuse
inside the membrane while the ionic strength of the media
induces the gel of the RAD16-I. Finally 160 𝜇L of fresh media
was added in each well and samples were cultured under
standard conditions (37∘C and 5% CO
2
).
2.5. In Vitro Characterization of SubATDPCs Loaded in
Composites (Bioimplant)
2.5.1. Study of Gene Expression by RT-PCR. Reverse tran-
scription polymerase chain reaction (RT-PCR) was per-
formed to analyse gene expression in 2D and bioimplant
cultures. The samples were lysed, and RNA was extracted
with PeqGold Total RNA kit (Peqlab) and followed by
cDNA synthesis using Quantitect Reverse Transcription Kit
(Qiagen) according to manufacturer protocol. PCR reaction
was carried out using 30 ng of cDNA in a final volume of
25 𝜇L containing 1XThermoPol Reaction Buffer (stock 10X),
0.42 units of TAQDNApolymerase (SigmaAldrich), 200 𝜇M
of dNTPs (Sigma Aldrich), and 0.3 𝜇M primers. The PCR
took place under the following conditions: 3min at 95∘C
(activation) followed by 35 cycles of 20 s at 94∘C, 30 s of
annealing (𝑇
𝑚
dependent on primer pair; see supplementary
Table 1) and 30 s at 72∘C. Final extension step was performed
at 72∘C during 15min. PCR products were size fractionated
by 2 or 4% agarose gel electrophoresis, depending on the
expected fragment size.
2.6. In Vivo Characterization of the Bioactive Implant
2.6.1. Genetic Labelling of SubATDPCs. Cells were transduced
(2 × 106 transducing units/mL, MOI = 21, 48 h) with CMVp-
RLuc-mRFP1 lentiviral vector, which contains a chimeric
construct of the Renilla reniformis luciferase (RLuc) reporter
gene and monomeric red fluorescent protein (mRFP1) under
transcriptional control of the cytomegalovirus (CMV) pro-
moter [55].
2.6.2. Myocardial InfarctionModel. The study was performed
on 8 female SCID mice (20 to 25 g; Charles River Laborato-
ries, Inc.). Myocardial infarction was created as previously
described [18], occluding the LAD coronary artery which
provokes and acute infarct. The animals were randomly
assigned to one of the following groups: (1) PEA-bioimplant
implantation and no MI induction (the PEA sham group,
𝑛 = 2), (2) MI induction and PEA-bioimplant implantation
(𝑛 = 2), (3) PCLMA-bioimplant implantation and no MI
induction (the PCLMA sham group, 𝑛 = 2), and (4) MI
induction and PEA-bioimplant implantation (𝑛 = 2). The
bioimplants were implanted immediately after occlusion.
2.6.3. Assembly and Transplantation of the Bioimplant. The
bioimplants were cultured in standard conditions for 24 h
before implantation onto the healthy or the infarcted
myocardium of mice, making use of synthetic surgical glue
(Glubran 2) to fix their edges to the tissue and avoid sliding.
Three-day postimplantation hearts were arrested in diastole
with arrest solution (68.4mM NaCl, 59mM KCl, 11.1mM
Glucose, 1.9mM NaHCO
3
, 29.7mM BDM (2,3-butanedione
monoxime), 1000UHeparin).Then the sampleswere excised,
fixed, cryopreserved in 30% sucrose in PBS, embedded in
OCT (Sakura), and snap-frozen in liquid nitrogen-cooled
isopentane. Tissue blocks were stored at −80∘C until section-
ing.
2.6.4. Noninvasive Bioluminescence Imaging (BLI) of Lucifer-
ase Activity from Bioimplant. Anesthetized mice, bearing a
bioimplant seeded with PLuc expressing cells, were intraperi-
toneally injected with 150 𝜇L of luciferin for in vivo BLI
(16.7mg/mL in physiological serum) (Caliper, Hopkinton,
MA). Mice were monitored right after implantation and
before sacrifice. Quantification and analysis of photons
recorded in images were done using the Caliper image
analysis software (Caliper, Hopkinton, MA).
2.6.5. Histology and Immunohistochemistry. Mouse heart
cryosections were stained withMasson’s trichrome (collagen:
blue, myocardium: red) and photographed using a TL RCI
stereoscope (Leica) for morphology evaluation. Addition-
ally, sections were incubated with the primary antibodies
against cTnI (2 𝜇g/mL) (Abcam) andRFP (2 𝜇g/mL) (Abcam)
to enhance cells detection. Actin fibres were stained with
Phalloidin Alexa568 (1 : 40, Invitrogen). Nuclei were counter-
stained with Hoechst 33342 and results were analysed with
Leica TCS SP2.
2.7. Statistical Analysis. All values were expressed as mean ±
standard deviation. Samples were prepared in triplicate for
each condition analysed.
3. Results
3.1. Composite Development (Elastomeric Membrane +
RAD16-I Self-Assembling Peptide). The architecture of devel-
oped scaffolds was analysed by SEM in a frontal view and
cross section (Figure 2).
Cylindrical interconnected orthogonal pores of PEA
scaffold can be clearly observed in a cross section image
(Figure 2(b)) and different layers of cylindrical crossed pores
in parallel and perpendicular planes can be visualized
(Figure 2(a)). On the other hand, interconnected spherical
pores of PCLMAscaffolds can be easily appreciated providing
a trabecular regular aspect (Figures 2(e) and 2(f)).
The measured porosities of both types of scaffolds,
swelling in PBS, water contact, angle, and their apparent
tensile moduli (together with the tensile moduli of the bulk
respective samples) are listed in Table 1. Although the values
obtained for PCLMA scaffolds are slightly higher than those
for PEA; for both it can be stated that they are highly porous
and have a hydrophobic character and elasticity typical of
elastomeric polymers. Since they differ in their chemical
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Table 1: Structural and mechanical parameters of the elastomeric
membrane. Morphological parameters (porosity, 𝜋, equilibrium
water content in PBS, EWC, water contact angle and Young
modulus, 𝐸) of PEA scaffolds with cylindrical orthogonal pores and
PCLMA scaffolds with spherical pores. Young modulus between
brackets corresponds to the bulk PEA and PCLMA polymers.
𝜋 (%) EWC (%) Contactangle (∘) 𝐸 (MPa)
PEA 76.4 ± 6.1 1.14 ± 0.16 115 ± 0.95 0.04 ± 0.02(0.84 ± 0.08)
PCLMA 89.0 ± 1.0 10.00 ± 0.73 123.46 ± 1.50 0.40 ± 0.08(0.73 ± 0.07)
composition and architecture (sizes and shape of pores and
interconnectivity), their biological performances will likely
be different.
The Young moduli herein obtained may differ slightly
when the scaffolds are filled with the weak peptide hydrogel
gel and loaded with cells. Nonetheless, it can be safely stated
that the stiffness of any of the proposed cardiac patches will
closelymatch the values reported for the heartmuscle ofmice
after dissection (0.06MPa) and the ones of rat or human (0.14
or 0.2–0.5 MPa, resp., at the end of diastole) [12, 56, 57].
The loading of the self-assembling peptide RAD16-I
into the elastomeric membranes was carried out prior to
the loading of the cells. Both elastomeric membranes are
hydrophobic (none of them swells more than 10% in PBS,
Table 1). For this reason, vacuumwas used to force the viscous
self-assembling peptide solution to get into the membrane,
and a subsequent in situ gelling was carried out successfully
with the diffusion of an ionic solution.ThepositiveCongo red
staining (Figures 2(c) and 2(g)) indicates that the formation
of the gel leads to a𝛽-sheet structure and the cryoSEM images
(Figures 2(d) and 2(h)) confirm that the scaffolds’ pores are
uniformly filled with the peptide gel. The hydrogel is shown
as a honeycomb-like structure after sublimation of water.
Although the quantity of RAD16-I cannot be quantified, the
complete filling of the pores has been assessed.
3.2. Electrical Resistivity of the Composites. The electrical
resistivity of the composites was analysed, and data were nor-
malized. Electrical resistivity of 53.0 ± 8.5Ω⋅m was obtained
for PEA membrane while 52.8 ± 5.5Ω⋅m was obtained
for PCLMA (Table 2). By comparing PEA and PCLMA
membranes, it can be observed that both membranes studied
present similar electrical resistivity.
3.3. In Vitro Characterization of SubATDPCs Cultured in
Monolayer. SubATDPCs were spindle-shaped and clono-
genic and had a duplication time of 3.1 ± 0.03 days at
passage 2 when seeded at a density of 1000 cells/cm2 (Supple-
mentary Figure 1A). Immunophenotypical characterization
of the cells revealed a mesenchymal stem-cell- (MSC-) like
pattern, with a high percentage of subATDPCs staining
strongly positive for CD105, CD44, CD166, CD29, and CD90
and negative for CD106, CD45, and CD14 (Supplementary
Figure 1B). Comparable to the case of bone marrow-derived
Table 2: Electrical parameters of the composite. Electric impedance
values at 10 KHz for PEAandPCLMAscaffolds previously filledwith
RAD16-I 0.15% self-assembling peptide and healed transmural and
nontransmural myocardium.
𝜌 (Ωm)
PEA 53.0 ± 8.5a
PCLMA 52.8 ± 5.5a
Infarcted nontransmural myocardium 122 ± 27b




MSCs [58], subATDPCs were able to inhibit peripheral blood
lymphocyte proliferation (an 82% proliferation reduction),
indicating an immunosuppressive capacity of subATDPCs.
Moreover, culture of subATDPCs in adipogenic or osteogenic
differentiation media resulted in intracellular accumulation
of lipid droplets and calcium deposition, respectively, indi-
cating adipogenic and osteogenic differentiation potentials
(Supplementary Figure 1C) [59]. In addition, these cells have
been analyzed for the expression of cardiac markers and
their cardiac differentiation under electric stimulus by Llucia`-
Valldeperas et al. [60].
3.4. Bioimplant Preparation (Elastomeric Membrane +
RAD16-I Self-Assembling Peptide + SubATDPCs). Once as-
sessed the correct introduction of RAD16-I nanofiber peptide
inside the elastomeric membrane, subATDPCs suspended in
medium were loaded on the constructs.
During shaking, the cells were allowed to diffuse while
the high ionic strength of the media induced the self-
assembly of RAD16-I. After 1 and 4 days of in vitro culture,
the bioimplants were removed from the well plate, and we
analysed gene expression. The morphology of the cells after
7 days of in vitro culture can be observed in Figure 3. Cells
grew mostly at the surface of the construct of both types
of elastomeric membranes, indicating that, in vitro, they
were unable to invade the scaffolds completely. The surfaces
were, though, totally covered by cells after this culture time.
DAPI/Phalloidin staining in Figures 3(g) and 3(h) shows how
some cells have been able to migrate inside the construct
during the first days of culture, but most remain on the
surface.
3.5. Study of Gene Expression by RT-PCR. RT-PCR analysis
was performed to assess the possible cardiac profile of the
cells after 1 and 4 days (Figure 4) of culture. Day 1 samples
show gene profile before implantation of the bioimplants
in mice, and day 4 presents gene profile of the bioimplant
cultured in vitro for 4 days, which coincides with the length
of the in vivo experiments (1 day of preculture and 3 days
of follow-up after implantation). Interestingly, expression
of early cardiac markers such as TBX5 (T-box transcrip-
tion factor 5), MEF2C (Myocyte Enhancer Factor 2C), and
some definitive cardiac markers such as ACTN1 (Actinin,
alpha1), cTnT (Troponin T2), and GJAI (Connexin-43) can




Figure 1: RECATABI concept scheme. Elastomeric membrane pores completely filled with the self-assembling peptide RAD16-I and
subATDPCs growing on and inside the composite. ∗The pores of the scheme are spherical but different architectures can be used.
be observed. Additionally, expression of CDH1 (E-Cadherin)
and SNAI1 (Snail Family Zinc Finger 1, a natural repressor of
CDH1) were analysed.
No important differences were detected between day 1
and day 4 on gene expression except for cTnT, which was
downregulated in the composite but was upregulated again
in PCLMA at 4 days of culture. In addition, the expression
of CDH1 in both composite systems used was downregu-
lated. All these results indicate that the composite is not
cardioconductive since no difference between materials can
be observed, but it is able to maintain the cardiac fate of
subATDPCs.
3.6. In Vivo Implantation. With the intention of monitoring
cell survival and distribution of the implanted cells after
the bioactive patch implantation, a noninvasive biolumi-
nescence imaging (BLI) system was used. Cells within the
bioimplant were previously labelled with CMV:Rluc:RFP:ttk
photoprotein reporters for BLI and fluorescence detection.
Photon counts quantification showed human subATDPCs
survival and thoracic location three days after implantation
of PEA and PCLMA bioimplants (supplementary data).
Moreover, whole heart excision and histology examination
demonstrated correct position of the bioactive implant on the
infarcted area (Figures 5(A)–5(D)).
Three days after implantation, subATDPCs within the
PEA bioimplant were homogeneously distributed giving
some of them an elongated shape (Figure 5(E)). On the other
hand, PCLMA bioimplant cells were mainly distributed in
the borders of the myocardium (My) or inner membrane
(im) and only few were found in the outer membrane (om)
(Figure 5(I)). Both bioactive implants were attached to the
heart (Figures 5(C), 5(D), 5(F), and 5(I)), and few cells already
started migration to the damaged myocardium (Figures 5(G)
and 5(J)).
4. Discussion
The high impact of MI worldwide leads a lot of researchers
to focus their attention on cardiac tissue engineering (CTE)
with the aim to obtain an effective approach for necrotic tissue
repair. CTE’s success highly depends on the choice of the
appropriate cell source [7, 8], and the biomaterial [61] used
as a vehicle to graft the cells in the infarcted tissue. Here, we
propose a combination of an elastomeric membrane and a
self-assembling peptide combining their intrinsic properties
and obtaining a more adaptable patch. Different types of
material-based approaches have been developed with the
aim to improve cardiac function after myocardial infarction
to avoid heart failure [62]. One of these approaches is the
use of biomaterials to constrain the post-MI failing heart,
preventing it from further remodeling and dilatation [63–
66]. Our design aims to avoid ventricle dilatation using a
nondegradable or semidegradable material and at the same
time provides the cells a biological, biophysical, andmechan-
ical support for their growth, function, self-renewal, and
differentiation thanks to RAD16-I peptide. We think that the
combination of elastomeric membranes with self-assembling
peptide RAD16-I solves both issues (see Figure 1). From
macroscopically point of view the elastomeric membranes
can fit the implantation site and do not affect negatively the
remaining performance of the heart due to their intrinsic
elasticity. These materials are elastic enough to not restrain
the remaining contractility of the heart but at the same time
can avoid the negative dilatation due to matrix remodeling.
Additionally, they maintain their original dimensions after
implantation (do not swell) and have mechanical moduli
similar to soft tissues. On the other hand, RAD16-I peptide
could provide an adequate interface between the elastomeric
membranes and the cells, enhancing their binding, signalling,
and proper interaction.
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Figure 2: Elastomeric membrane and composite characterization. Microscopic images of the ((a)–(d)) PEA scaffolds with cylindrical
orthogonal pores and ((e)–(h)) PCLMA scaffolds with spherical pores. ((a) and (e)) SEM images, cross section, and ((b) and (f)) SEM images,
surface. ((c) and (g)) Congo Red staining and ((d) and (h)) cryoSEM images of the scaffolds loaded with 0.15% RAD16-I and gelled with PBS,
surface. White arrows point out the elastomeric membrane while the black ones point out the self-assembling peptide structure after gel.
Two chemically and architecturally different elastomeric
membranes were tested: PEA scaffolds with cylindrical
orthogonal pores and PCLMA ones with spherical pores.
Both membranes are elastic enough to withstand the stresses
arising from heartbeat and ensure stable placement of seeded
cells under those conditions as it can be observed in Figure 5.
With the aim to provide an adequate microenvironment,
the membranes’ pores were filled with RAD16-I nanofiber
peptide, since previously it was demonstrated that the use
of RAD16-I peptide inside the elastomeric membrane porous
increases the seeding efficiency [45]. The peptide was intro-
duced into both porous structures simply by pressure (see
Figure 1). One additional advantage of these macroporous
scaffolds is their capacity to allow the development of
microvasculature in vivo [67]. Unfortunately, as the animal
model used is analyzed at a really short term (3 days), the
formation of vessels is not plausible and for this reason it was
not analyzed. In vitro experiments at day 7 show a limited
cell distribution with the cells remaining in the surface of
the scaffold, but 3 days after implantation, cell distribution
and penetration were dramatically enhanced. In vitro, the
cell distribution remains mainly limited to the surface of
the composite provably due to the difficulty of oxygen and
nutrients diffusion inside the structure. After implantation
of the patch on the infarcted heart the conditions change
dramatically mainly due to the new environment, which is
different from the previous culture system. Since it is a model
of acute MI immediately after the intervention, the necrotic
heart tissue creates an unfriendly environment which causes
the implanted cells to migrate towards the contrary direction
(inside the composite).
From an electrical standpoint, it is well known that the
electrical resistivity is lower and less frequency dependent
in necrotic than in healthy myocardium [68, 69]. According
to the values reported in Table 2, it can be observed that
the resistivity values for the composites are below infarcted
nontransmural and transmural myocardium resistivity, but
the resistivity value of normal myocardium is larger com-
pared to infarcted myocardium (250Ω⋅cm at 10 kHz) [51].
We think that the resultant equivalent resistance coming
from the parallel combination of the infarcted tissue and
the scaffold will actually benefit the electrical coupling with
native myocardium tissue. Based on the simple circuit theory
principle, which confirms that the equivalent resistance of
two resistances in parallel is equal or lower than the lowest
resistance, the scaffold will provide a low-resistance pathway
that should contribute to facilitating the electrical signal
propagation from the native heart tissue into the scaffold.
Thus, we speculate that both composites, which have similar
electrical resistivity, will equally facilitate the propagation of
electrical pulses throughout the contact area between the
composites and the infarcted zone.
Since both materials presented are candidates to be
used for cell therapy, they were loaded with subATDPCs
(see Figure 1). The identity of progenitor cells, during early
cardiogenesis, is regulated by tightly coordinated, spatially
and temporally active signaling pathways and molecular
mechanisms. This leads cells to a progressive restriction of
undifferentiated progenitors to the different cardiovascular
lineages. The molecular identity of these inductive signals is
not well understood, but various transcription factors that
may regulate cardiac commitment and differentiation have
been isolated [70].
The in vitro genetic profiles of such cells cultured in both
composites were analysed before their in vivo implantation.
Interestingly, TBX5 [71, 72] and MEF2C [73] early cardiac
markers and definitive cardiac markers such as ACTN1,
cTNT, and GJAI were expressed [74]. TBX5 is a member
of T-box gene family [75] critical for the development of
the heart. Its expression is critical to the formation of the
electrical system that coordinates contractions of the heart
chambers. It has been shown to interact with MEF2C to












Figure 3: Bioimplant characterization. Microscopic images of subATDPCs growing in developed composite after 7 seeding days. (a) Surface
of PEA scaffold; (b) surface of PCLMA scaffold; ((c), (d)) close up of top PEA, and PCLMA scaffold respectively; (e) PEA scaffold cross section;
(f) PCLMA scaffold cross section; and ((g) and (h)) Dapi & Phalloidin staining of subATDPCs in PEA and PCLMA scaffold. In images (a)
to (f) white arrows indicate the cells growing in the bioactive implant, black arrows note the nanofibers of self-assembling peptide RAD16-I,
and red arrows signalize the structure of porous elastomeric membrane. White arrows in image (g) and (h) indicate scaffolds surface while
orange arrows indicate cells migrating inside the composite. Scale bars: (a) 30 𝜇m; (b), (E)–(H) 100 𝜇m; (c) 3 𝜇m; and (d) 5 𝜇m.
synergistically activate target genes expression in cardiomy-
ocytes [72]. MEF2C is a MDS-box transcription factor which
plays a key role in myogenesis [76], specifically controlling
the differentiation of cardiomyoblasts into cardiomyocytes
[77] (see Figure 6). On the other hand, a decrease of CDH1
expression with respect to cells growing in 2D culture was
observed, although SNAI1 repression factor was maintained.
CDH1 and GJAI genes encode for cell connection proteins.
























Figure 4: Expression of cellular markers in developed bioimplant by RT-PCR. Cardiogenic and general markers expressed by subATDPCs
cultured in developed patch of PEA and PCLMA after 1 (d1) and 4 (d4) days of culture in vitro compared to two-dimensional (2D) cultures.
NC: negative control (PCR without template).
CDH1 [78] is involved in mechanisms regulating cell-cell
adhesions, mobility, and proliferation while GAJ1 provides
a route for the diffusion of low molecular weight materials
from cell to cell having a crucial role in the synchronized
contraction of the heart. As suggested by the results shown
in Figure 5, these cells are capable of migrating either inside
the membrane or to the infarcted area after implantation.
It is important to mention that most of the studied genes
presented the same pattern for all conditions, but cTNT
was only expressed in the PCLMA bioactive implant after
4 days in vitro. Therefore, it seems that subATDPCs are
maintaining their gene profile, which indicates that they tend
to preserve their cardiogenic potential lineage, at least in
vitro. These results lead us to conclude that the proposed
materials combined with RAD16-I are not cardioconductive
materials, but the cardiomyogenic potential of subATDPCs is
maintained [60].
The in vitromodel gives an overview of the patch poten-
tial, but in any case these results could be extrapolated to the
in vivo scenario. Here, a proof of concept of short time points
was developed to analyse the patch feasibility in terms of
integration and cell viability. Interestingly, we notice that both
patches intimately attach to the myocardium. Additionally,
both remained in the position at the infarction area where
they were placed suggesting some resilience to the heart
mechanical forces and, in addition, 3 days after implantation
the cells remained alive and mostly at the thoracic area
(Figure 2, supplementary data). Although both bioactive
implants were attached to the myocardium, the PCLMA
bioimplants showed greater cell immobilization and better
integration in the infarcted area than the PEA ones. Cells
growing inside the PEA bioimplants were homogenously
distributed, acquiring some elongated shape (Figures 5(E)
and 5(F)) while, in the PCLMA ones, cells were mainly
distributed at the interface between the bioimplant and the
myocardium (Figure 5(I)). We did not expect to observe
profusely cell migration at such short time assay, but we
speculate that the cellsmight start to contribute to a paracrine
effect by secreting specific factors; phenomena previously
reported using MSC and cardiomyocytes in rat and mice
models, respectively [79–81]. Importantly, in previous studies
an increase of vascularization and a reduction of infarct size
after ATDPCs injection were reported [45]. Therefore, their
better retention onto the infracted tissue using this platform
might lead to positive benefits by the stimulation of vessel
formation. Further in vivo studies at longer time points will
be performed with the aim to analyse the beneficial role of
these bioactive patches in vivo.
5. Conclusions
PEA- and PCLMA-based bioimplants developed provide
a good platform for cell therapy aiming to assist tissue
restoration of the infarcted ventricular area. Importantly, the
scaffold plus peptide gel composite devices brings a suitable
microenvironment where cells can be retained alive at the
implanted site, which is an improvement of the proposed to
date direct cell injection therapies. Moreover, these patches
permit cells to maintain their genetic profile enhancing their
therapeutic potential at the time of being implanted. Finally,
all these characteristics could improve the cell capacity to
provide a positive paracrine effect on resident cells in the
host tissue, whichmight improve the recovery of the infarcted
zone.










Figure 5: General view of the PEA and PCLMA bioactive implants on mice heart after 3 days. (a) Whole heart excision and macroscopic
examination. ((A) and (B)) Macroscopic view of mouse heart and bioactive implant (outlined) at 3 days after implantation, and ((C) and
(D)) Masson’s trichrome staining of heart with bioactive implant cross section.The dotted zone in black corresponds to the bioactive implant
and the dotted red area to the infarcted zone. (b) Microscopic view of the bioactive implant. ((E) and (H)) Detail of elongated subATDPCs
(red) inside the PEA (E) and PCLMA (H) bioactive implants; ((F) and (I)) views of the PEA (F) and PCLMA (I) bioactive implants attached
to the myocardium (implant and myocardium are limited by dotted lines (Phalloidin staining in red)); and ((G) and (J)) migration of the
subATDPCs (white arrows) to the myocardium (cTnI staining in white) in PEA (G) and PCLMA (J) groups. Constitutive expression of RFP
(red) in subATDPCs. Nuclei were counterstained withHoescht 33342 (blue). Scale bars 1mm ((A)–(D)), 50 𝜇m ((E)–(H) and (J)), and 100 𝜇m
(I).






















Figure 6: Sequential steps in cardiac differentiation in vitro from pluripotent stem cells to functional cardiomyocytes [70]. Cardiac
development starts with the commitment of undifferentiated pluripotent stem cells of the inner cell mass of blastocysts to mesodermal
restricted derivatives during embryonic development. Typical markers and characteristics for the different cell types are indicated. Structural
and functional maturation is not well understood. Maturation might be provoked by hormones, electrical and mechanical stimulation, and
organization in 3D engineered heart tissues (EHTs).
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